Novo Nordisk A/S (ADR) news

   Watch this stock
Showing stories 11 - 20 of about 115   

Articles published

NVO 47.91 +1.33 (2.86%)
price chart
Novo Nordisk A/S (ADR) Anti-Obesity Drug Approved By European Commission
Novo Nordisk A/S (ADR) (NYSE:NVO), has another victory to add to its success story: its obesity drug Saxenda has won marketing authorization from the European Commission as announced on Monday.
Novo Nordisk A/S, Sanofi SA, Merck & Co Top $62 Billion Diabetes Market In ...
According to a report compiled by data analytics firm GlobalData, the 10 leading diabetes drug-makers generated around $62 billion in 2014 global sales, up 5.1% year-over-year (YoY).
Novo Nordisk A/S (ADR) Shoots Up On Plans To Resubmit NDAs Of Tresiba And ...
Novo Nordisk A/S (ADR) (NYSE:NVO), the world's largest insulin-maker, announced Thursday its plans to resubmit New Drug Applications (NDAs) of its long-acting insulin candidate Tresiba and related drug Ryzodeg to the US Food and Drug Administration ...
Novo Nordisk to Submit Interim DEVOTE Data to the FDA - Analyst Blog  Nasdaq
New Deal Between Emisphere Technologies Inc. (EMIS) and Novo Nordisk A/S (ADR ...
On October 15, Emisphere Technologies Inc. (OTCMKTS:EMIS) announced an agreement with Novo Nordisk A/S (ADR) (NYSE:NVO) to develop and market oral formulations of four classes of the Danish company's investigational molecules targeting ...
Emisphere Signs License Agreement With Novo Nordisk to Develop Oral ...  FierceDrugDelivery
Novo Nordisk Rallies; Signs Antibody Development Deal With Genmab
Novo Nordisk A/S (ADR) (NYSE:NVO) stock is trading up today, after the Danish pharmaceutical company Genmab A/S agreed to grant the insulin-maker two commercial licenses for using its DuoBody technology platform.
Lars Rebien Sorensen: The Man Behind Novo Nordisk
Sorensen's ability to lead a healthcare company was put to test just six months into his job as Novo Nordisk's A/S (ADR) (NVO) CEO. The company had received a lot of heat for suing the South African government in a patent fight related to drugs that ...
Related articles »  
Most Active Stocks in Focus: Novo Nordisk A/S (ADR) (NVO), Ingersoll-Rand PLC (IR)
The Company moved -3.97% down right now and is at $49.65. Stock is trading in the real-time trading session with the total volume of 1.52 million shares, as compared to its average volume of 1.26 million shares.
CHMP Gives Positive Opinion On Novo Nordisk's Obesity Drug Saxenda
Yesterday Novo Nordisk A/S (ADR) (NYSE:NVO) said that it has received a positive verdict from the Committee for Medicinal Products for Human Use (CHMP), for its obesity drug Saxenda.
Novo Nordisk To Go Ahead With Russian Investment
The world's largest insulin-maker, Novo Nordisk A/S (ADR) (NYSE:NVO) is going ahead with its investment plans for Russia, even after the ruble's drastic fall.
Novo Nordisk (NVO) Wins FDA Nod For Weight-Loss Injection
Novo Nordisk A/S (ADR) (NYSE:NVO) announced Wednesday that the US Food and Drug Administration (FDA) has approved its experimental weight-loss injection, Saxenda, to treat obesity in adults.
The Newest FDA-Approved Obesity Drug Is Also the Oldest  Motley Fool
Related articles »